Print

pSivida Corp (PSDV) Announces Germany Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema  
7/26/2012 10:13:24 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) has granted marketing authorization to ILUVIENĀ® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
//-->